Identification in Obese Patients of the Mechanism Involved in Intramuscular Lipid Accumulation
Not Applicable
Completed
- Conditions
- ObesityInsulin ResistanceHyperlipidemia
- Registration Number
- NCT01644942
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
The study aims to determine in obese patients the implication of intramuscular lipid accumulation in relation with insulin resistance and defect in lipid oxidation.
- Detailed Description
Obese insulin sensitive and obese insulin resistant patients undergo a glucose tolerance test, indirect calorimetry during exercise and muscular biopsy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 33
Inclusion Criteria
- Obese patients with a Body Mass Index (BMI) between 30 and 40 kg/m2
- Patients who do not practice physical exercise (Voorips index < 9)
- Age between 40 and 70 years- Male gender
- Fast blood glucose <1,10 g/l and no hypoglycemic treatment
- Signed informed consent
- Social security affiliation
- Absence of anti VIH, anti hepatitis C antibodies, and HBS antigen
- Normal biological tests
- Non smoking persons
Exclusion Criteria
- Patients who refuse the anti-VIH, anti-hepatitis C antibodies, and HBS antigens tests
- Patients treated by anticoagulant, b blockers, lipopenic, or anti-inflammatory.
- Patients with a contraindication to muscular exercise (retinopathy, coronaropathy, nephropathy) and to muscular biopsy
- Allergy to local anaesthetic
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method lipid accumulation in skeletal muscle 1 month
- Secondary Outcome Measures
Name Time Method lipid accumulation in myotubes from obese patients 1 month
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways mediate intramuscular lipid accumulation in insulin-resistant obese patients from NCT01644942?
How does intramuscular lipid analysis in NCT01644942 compare to thiazolidinediones in improving insulin sensitivity in obese patients?
Which metabolic biomarkers predict intramuscular lipid accumulation and insulin resistance in NCT01644942 participants?
What are the potential adverse events of muscle biopsy in NCT01644942 and how are they managed in obese patients?
Are there combination therapies targeting lipid oxidation and insulin signaling that build on NCT01644942's findings in obesity?
Trial Locations
- Locations (1)
CHRU Montpellier
🇫🇷Montpellier, France
CHRU Montpellier🇫🇷Montpellier, France